Guest guest Posted May 15, 2011 Report Share Posted May 15, 2011 May 15, 2011 SSpecial Bulletin HCV » May Newsletter » HCV Fact Sheets » Educational Materials » HCSP Streaming Videos Dear Reader : I am happy to be able to tell you that a major advancement in treatment for people with chronic hepatitis C genotype 1 was approved by the Food and Drug Administration-the combination of Victrelis (boceprevir), pegylated interferon and ribavirin (Merck & Co.). HCSP is gearing up to provide extensive updates and education to the HCV community. To this end we have updated more than 40 fact sheets and will continue to update our fact sheets and guides as more information becomes available. A decision from the FDA about the approval of Incivek (telaprevir)-in combination with pegylated interferon plus ribavirin-is expected towards the end of the month. This will mean that people with HCV genotype 1 will have even more treatment options. The approval of Victrelis and the pending approval of Incivek will mean that May 2011 will be a truly incredible month for people living with HCV-maybe we are finally turning the corner on this devastating disease-at least in regards to even more effective medications to treat all populations with HCV. Alan Join us on Twitter - Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate www.hcvadvocate.org Editor-in-Chief, HBV Advocate www.hbvadvocate.org **Questions and Comments: If you have questions or comments please do not reply to this email. Questions and/or comments can be directed to alanfranciscus@... HBV » HBV Journal Review » HBV Factsheets » HBV & HCV Advocate Hepatitis Blog » Stay connected with all the late-breaking news on hepatitis B-Join us on Twitter Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.